These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
395 related articles for article (PubMed ID: 29667155)
1. Association of cerebrospinal fluid Neurogranin with Alzheimer's disease. Wang L; Aging Clin Exp Res; 2019 Feb; 31(2):185-191. PubMed ID: 29667155 [TBL] [Abstract][Full Text] [Related]
2. Increased neurogranin concentrations in cerebrospinal fluid of Alzheimer's disease and in mild cognitive impairment due to AD. Sanfilippo C; Forlenza O; Zetterberg H; Blennow K J Neural Transm (Vienna); 2016 Dec; 123(12):1443-1447. PubMed ID: 27531278 [TBL] [Abstract][Full Text] [Related]
3. CSF neurogranin levels as a biomarker in Alzheimer's disease and frontotemporal lobar degeneration: a cross-sectional analysis. Jurasova V; Andel R; Katonova A; Veverova K; Zuntychova T; Horakova H; Vyhnalek M; Kolarova T; Matoska V; Blennow K; Hort J Alzheimers Res Ther; 2024 Sep; 16(1):199. PubMed ID: 39242539 [TBL] [Abstract][Full Text] [Related]
4. Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer's disease. Hellwig K; Kvartsberg H; Portelius E; Andreasson U; Oberstein TJ; Lewczuk P; Blennow K; Kornhuber J; Maler JM; Zetterberg H; Spitzer P Alzheimers Res Ther; 2015 Dec; 7():74. PubMed ID: 26698298 [TBL] [Abstract][Full Text] [Related]
5. Association of cerebrospinal fluid neurogranin levels with cognition and neurodegeneration in Alzheimer's disease. Xue M; Sun FR; Ou YN; Shen XN; Li HQ; Huang YY; Dong Q; Tan L; Yu JT; Aging (Albany NY); 2020 May; 12(10):9365-9379. PubMed ID: 32421689 [TBL] [Abstract][Full Text] [Related]
6. The Effects of CSF Neurogranin and Fan Y; Gao Y; Therriault J; Luo J; Ba M; Zhang H; Front Aging Neurosci; 2021; 13():667899. PubMed ID: 33986657 [TBL] [Abstract][Full Text] [Related]
8. Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease. Kester MI; Teunissen CE; Crimmins DL; Herries EM; Ladenson JH; Scheltens P; van der Flier WM; Morris JC; Holtzman DM; Fagan AM JAMA Neurol; 2015 Nov; 72(11):1275-80. PubMed ID: 26366630 [TBL] [Abstract][Full Text] [Related]
9. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease. Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O; JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367 [TBL] [Abstract][Full Text] [Related]
10. Cerebrospinal fluid levels of YKL-40 in prodromal Alzheimer's disease. Wang L; Gao T; Cai T; Li K; Zheng P; Liu J; Neurosci Lett; 2020 Jan; 715():134658. PubMed ID: 31794792 [TBL] [Abstract][Full Text] [Related]
11. The Cerebrospinal Fluid Neurogranin/BACE1 Ratio is a Potential Correlate of Cognitive Decline in Alzheimer's Disease. De Vos A; Struyfs H; Jacobs D; Fransen E; Klewansky T; De Roeck E; Robberecht C; Van Broeckhoven C; Duyckaerts C; Engelborghs S; Vanmechelen E J Alzheimers Dis; 2016 Jul; 53(4):1523-38. PubMed ID: 27392859 [TBL] [Abstract][Full Text] [Related]
16. Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease. Mandecka M; Budziszewska M; Barczak A; Pepłońska B; Chodakowska-Żebrowska M; Filipek-Gliszczyńska A; Nesteruk M; Styczyńska M; Barcikowska M; Gabryelewicz T J Alzheimers Dis; 2016 Jul; 54(1):157-68. PubMed ID: 27472875 [TBL] [Abstract][Full Text] [Related]